Vaccines Targeting Dendritic Cells
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Cellular/Molecular Immunology".
Deadline for manuscript submissions: 28 February 2025 | Viewed by 61
Special Issue Editors
Interests: dendritic cell (subsets); cytotoxic T cells; viral infections; cancer; biomarkers
Interests: Langerhans cells; dendritic cells (subsets); immune regulation; inflammation; cancer
Special Issue Information
Dear Colleagues,
Dendritic cells (DCs) act as the sentinels of the immune system and initiate and orchestrate immune responses. Current DC-based immunotherapy approaches have shown promise in cancer treatment and prevention. These approaches involve the activation of DCs following the in vitro and in vivo delivery of antigens directly to them using specialized systems such as nanoparticles or viral vectors. These strategies aim to induce humoral immunity, prime T helper cells, and/or elicit CTL responses. Broadly, the role of DCs in modulating adaptive immune responses offers new avenues for vaccine development.
This Special Issue aims to compile the latest research on the ongoing advancements in vaccines targeting DCs. We welcome the submission of reviews, research articles, and short communications that highlight recent breakthroughs in DC-targeting vaccines, as well as manuscripts addressing the challenges and limitations encountered in this field.
Dr. Ronald A. Backer
Prof. Dr. Björn E. Clausen
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- vaccines
- dendritic cells
- antigen targeting
- immune responses
- adjuvant
- cancer immunotherapy
- T cell activation
